150 related articles for article (PubMed ID: 11142484)
1. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG.
Hoefnagel CA; Taal BG; Sivro F; Boot H; Valdes Olmos RA
Nucl Med Commun; 2000 Aug; 21(8):755-61. PubMed ID: 11039459
[TBL] [Abstract][Full Text] [Related]
3. Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG): pharmacological MIBG, 131I-labelled MIBG and the combination.
Zuetenhorst H; Taal BG; Boot H; Valdes Olmos R; Hoefnagel C
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1157-64. PubMed ID: 10524647
[TBL] [Abstract][Full Text] [Related]
4. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue.
Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B
Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846
[TBL] [Abstract][Full Text] [Related]
5. [131I]MIBG radionuclide therapy in carcinoid syndrome.
Taal BG; Zuetenhorst H; Valdés Olmos RA; Hoefnagel CA
Eur J Surg Oncol; 2002 Apr; 28(3):243. PubMed ID: 11944956
[No Abstract] [Full Text] [Related]
6. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
7. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.
Taal BG; Hoefnagel CA; Valdes Olmos RA; Boot H; Beijnen JH
J Clin Oncol; 1996 Jun; 14(6):1829-38. PubMed ID: 8656251
[TBL] [Abstract][Full Text] [Related]
8. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
9. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
10. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
11. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
[TBL] [Abstract][Full Text] [Related]
13. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases.
Prvulovich EM; Stein RC; Bomanji JB; Ledermann JA; Taylor I; Ell PJ
J Nucl Med; 1998 Oct; 39(10):1743-5. PubMed ID: 9776280
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
15. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.
Sywak MS; Pasieka JL; McEwan A; Kline G; Rorstad O
World J Surg; 2004 Nov; 28(11):1157-62. PubMed ID: 15490060
[TBL] [Abstract][Full Text] [Related]
16. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
17. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome.
Pathirana AA; Vinjamuri S; Byrne C; Ghaneh P; Vora J; Poston GJ
Eur J Surg Oncol; 2001 Jun; 27(4):404-8. PubMed ID: 11417988
[TBL] [Abstract][Full Text] [Related]
18. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
19. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
[TBL] [Abstract][Full Text] [Related]
20. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]